Latest stories on GALT
Galectin Therapeutics (GALT) Posts Q3 Earnings Beat with Narrower Loss
GuruFocus63 · neutralearnings
Galectin Therapeutics GAAP EPS of -$0.04 beats by $0.01
Seeking Alpha63 · neutralearnings
Galectin Therapeutics Reports September 30, 2026 Financial Results and Provides Business Update
Business Insider50 · neutralearnings
Galectin Therapeutics Reports September 30, 2026 Financial Results and Provides Business Update
GlobeNewswire50 · neutralearnings
GALECTIN THERAPEUTICS INC (GALT) files 8-K: Items 2.02, 9.01
SEC 8-K50 · neutralgeneral
Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026
GlobeNewswire63 · neutralproduct/pr
Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026
Business Insider56 · neutralproduct/pr
Galectin: $105M Debt Conversion Clears The Balance Sheet, But Phase 3 Partnership Is Critical
Seeking Alpha42 · neutralgeneral
Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire56 · neutralgeneral
Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Business Insider56 · neutralgeneral
Galectin Shares Slip on Wider Second-Quarter Loss
MarketWatch38 · neutralearnings
Galectin Therapeutics reports Q2 results
Seeking Alpha56 · neutralearnings
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
GlobeNewswire50 · neutralgeneral
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
Business Insider50 · neutralgeneral
GALECTIN THERAPEUTICS INC (GALT) files 8-K
SEC 8-K50 · neutralgeneral
Galectin Therapeutics strengthens balance sheet via debt-to-equity conversion
TipRanks63 · neutralgeneral
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
Business Insider59 · neutralgeneral
GALECTIN THERAPEUTICS INC (GALT) files 8-K
SEC 8-K50 · neutralgeneral
Galectin De-Risks Belapectin Path With FDA Alignment - Sets Stage For Phase 3 Upside
Seeking Alpha67 · bullishproduct/pr
GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial
Stocktwits News73 · bullishproduct/pr
Galectin Therapeutics Shares Surge on Positive FDA Meeting, Phase 3 Trial Plans
Morningstar73 · bullishproduct/pr
Galectin, FDA agree on late-stage trial design for MASH therapy
Seeking Alpha42 · neutralproduct/pr
Galectin Advances Belapectin to Phase 3 After FDA Alignment
TipRanks63 · neutralproduct/pr